



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Quarter / Three Months ended 30.06.2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly/ Three Monthly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)



Kopal Khanna
Partner


M.No. 416044

FRN No. 004025N

Date : 14.08.2015
Place : Chandigarh

CERTIFIED TO BE TRUE COPY

For Venus Remedies Limited



(Company Secretary)

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on August 14, 2015.
2. Investor Complaints pending during the beginning of the quarter-NIL, Received during the quarter-1, Disposed of during the quarter-1, Remaining unresolved at the end of the quarter-NIL.
3. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

**For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED**

Date : 14.08.2015

For VENUS REMEDIES LIMITED

(Pawan Chaudhary
CHAIRMAN & Managing Director

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30th JUNE, 2015

Amount (Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on		Year Ended on	
		30/06/2015 Unaudited	31/03/2015 Audited	30/06/2014 Unaudited	31/03/2015 Audited
Part – I					
1	Net Sales/ Income from operations				
	Gross Sales	987.11	985.47	1210.55	4504.05
	Less : Excise Duty	1.92	1.55	2.42	6.6
	(a) Net Sales	985.19	983.92	1208.13	4497.45
	(b) Other Operating Income	3.93	4.89	6.66	21.3
	Total Income from Operation (Net)	989.12	988.81	1,214.79	4,518.75
2	Expenses				
	(a) Consumption of raw materials	590.01	635.72	629.42	2,643.89
	(b) (Increase)/ Decrease in stock in trade	5.55	-22.63	49.12	65.28
	(c) Employee benefits expense	61.82	72.09	63.42	272.55
	(d) Depreciation & amortization expense	99.60	170.82	111.30	447.41
	(e) Other expenses	139.80	185.13	176.45	667.70
	Total expense	896.78	1,041.13	1,029.71	4,096.83
3	Profit from operations before other income , finance costs and exceptional items (1-2)	92.35	-52.32	185.08	421.92
	EBIDTA (3+2(d))	191.95	118.50	296.38	869.33
4	Other income	1.04	2.18	1.00	5.46
5	Profit before finance costs and exceptional items (3+4)	93.39	-50.14	186.08	427.38
6	Finance Costs	91.45	156.46	83.59	407.03
7	Profit after finance costs but before exceptional items (5-6)	01.93	-206.60	102.49	20.35
8	Exceptional items	0.00	0.00	0.00	00.00
9	Profit from ordinary activities before tax (7+8)	01.93	-206.60	102.49	20.35
10	Tax expense	0.00	0.00	0.00	25.13
11	Profit from ordinary activities after tax (9-10)	01.93	-206.60	102.49	45.48
12	Exceptional items (net of tax expense	00.00	00.00	00.00	0.00
13	Net profit for the period (11-12)	01.93	-206.60	102.49	45.48
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	0.00
16	E.P.S - Basic not annualized for the qtr	0.17	-18.06	8.96	3.97
	- Annualized	0.68	-72.23	35.83	3.97
Part – II					
1	Public Shareholding				
	- Number of Shares	7711988	7711988	7154551	7711988
	- Percentage of Shareholding	67.40	67.40	62.53	67.40
2	Promoters and promoter group shareholding				
	a) Pledged as collateral security to bank				
	- Number of Shares	3630000	3730000	1937250	3730000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	97.32	100.00	45.18	100.00
	- Percentage of shares (as a % of the total share capital	31.73	32.60	16.93	32.60
	b) Non-Encumbered				
	- Number of Shares	100000.00	0.00	2350187	0.00
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	02.68	00.00	54.82	00.00
	- Percentage of shares (as a % of the total share capital	00.87	00.00	20.54	00.00
Particulars		Quarter ended 30.06.2015			
(B) INVESTOR COMPLAINTS					
Pending at the beginning of the quarter		NIL			
Received during the quarter		1			
Disposed of during the quarter		1			
Remaining unresolved at the end of the quarter		NIL			

For **VENUS REMEDIES LIMITED**

 CHAIRMAN & MANAGING DIRECTOR